GLP-1 use is on the rise. In fact, current estimates (2026) are that 11% of the population is on a GLP-1, including easily accessible prescription and compounded forms. In certain populations, where medically indicated (type 2 diabetes, elevated lipids, high blood pressure) and/or patients with a significant amount of body weight to lose, these drugs have demonstrated significant benefits. “Quieting food noise” is a common refrain for individuals who take these drugs.

At the same time, these drugs are available to anyone, including individuals that 1) do not have a significant amount of weight to lose, and 2) do not demonstrate medical criteria to have a prescription for the GLP-1. Individuals may have access to GLP-1 medications (semaglutide, terzepitide) and use these powerful drugs to lose a small amount of weight and/or have a weight objective that is unrealistic and/or unhealthy.

Whatever the underlying issues may be, it is important to use these drugs responsibly and to evaluate clear objectives that are reasonable, realistic, and sustainable. As a clinician with decades of experience treating disordered eating and body image issues, it is important to develop healthy behaviors and set realistic goals in tandem with GLP-1 use.

Blog